Epidermal growth factor receptor (EGFR)-inhibitors, rashes, and survival: is doxycycline the missing link?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Oral Oncology

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.oraloncology.2010.02.003PMID 20189446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma--in vitro and in vivo studies.

  2010cited by this paper
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

  2010cited by this paper
• Role of matrix metalloproteinase-9 in lipopolysaccharide-induced mucin production in human airway epithelial cells.

  2009cited by this paper
• EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line.

  2009cited by this paper
• Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

  2009cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

  2007cited by this paper
• BASIC SCIENCE REVIEW

  2006cited by this paper
• Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

  2006cited by this paper
• Tetracycline analogues (doxycycline and COL‐3) induce caspase‐dependent and ‐independent apoptosis in human colon cancer cells

  2006cited by this paper
• Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy.

  2005cited by this paper
• Practical management of patients with non-small-cell lung cancer treated with gefitinib.

  2005cited by this paper
• Dermatologic side effects associated with gefitinib therapy: clinical experience and management.

  2003cited by this paper
• The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances

  2003cited by this paper
• Doxycycline and other tetracyclines in the treatment of bone metastasis.

  2003cited by this paper

• No citing papers are available for this paper.